BCM
ZNTL icon

Bayesian Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Bayesian Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,011
Closed -$226K – 1060
2023
Q2 		$226K Buy
+8,011
New +$192K 0.02% 610

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Bayesian Capital Management's ZNTL Position: Q3 2023 in Review

Bayesian Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2023, closing a stake of 8,011 shares — an estimated $226K sold.

Bayesian Capital Management first reported a position in ZNTL in Q2 2023 and held it in 1 quarter. The position peaked at $226K in Q2 2023. 137 funds tracked by Wall St. Rank hold ZNTL as of Q3 2023.

  • Bayesian Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 8,011 Zentalis Pharmaceuticals shares in Q3 2023, an estimated $226K.
  • Bayesian Capital Management first reported a position in Zentalis Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Bayesian Capital Management's Zentalis Pharmaceuticals position peaked at $226K in Q2 2023.
  • 137 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2023.

Based on Bayesian Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.